The present application relates to the treatment of autoimmune disorders, such as CIS or RRMS using biotin compositions. The present application also relates to the delay of progression from CIS to RRMS and RRMS to PPMS using biotin compositions. Also disclosed are methods of reducing pro-inflammatory cytokines using biotin compositions.